Precision Medicine in Oncology: Ep.11. Selection and use of PARP inhibitors for first-line maintenance treatment in ovarian cancer

IMPACT Medicom

English - May 02, 2022 14:00 - 15 minutes - 10.9 MB
Science impact medicom medical communications medical writing agency Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Immunotherapy in HNSCC Series: Ep 2 - Perspectives from Surgical Oncology

Next Episode: Immunotherapy in HNSCC Series: Ep 3 - Role of the Medical Oncologist

Welcome to episode 11 of our Precision Medicine in Oncology series. In this episode, we discuss the development of a pan-Canadian consensus paper on the selection and use of PARP inhibitors for first-line maintenance treatment in ovarian cancer.

Our Guest:
Our guest for this episode is Dr. Anna Tinker, Medical Oncologist at BC Cancer in Vancouver, Canada. Dr. Tinker is also a Clinical Associate Professor in the Department of Medicine at the University of British Columbia.

This podcast episode was sponsored by AstraZeneca Canada and Merck Canada.

If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com